Clinical Trial Update: A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating belantamab mafodotin for relapsed/refractory multiple myeloma; status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)

Snippet

Sponsor: Cristiana Costa Chase, DO | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 2 | Status: NOT_YET_RECRUITING